Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term outcome. The REPLACE study investigated the efficacy of switching to riociguat in patients with pulmonary arterial hypertension and an insufficient response to pho...
Main Authors: | Gérald Simonneau, Hossein-Ardeschir Ghofrani, Paul A. Corris, Stephan Rosenkranz, Ekkehard Grünig, Jim White, Vallerie V. McLaughlin, David Langleben, Christian Meier, Dennis Busse, Frank Kleinjung, Raymond L. Benza |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1177/2045894020973124 |
Similar Items
-
Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
by: Raymond L. Benza, et al.
Published: (2020-03-01) -
Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
by: Hossein-Ardeschir Ghofrani, et al.
Published: (2020-07-01) -
Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
by: Thenappan Thenappan, et al.
Published: (2020-11-01) -
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Raymond L. Benza, et al.
Published: (2022-10-01) -
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
by: Vallerie V. McLaughlin, et al.
Published: (2017-12-01)